LRP6-Targeting mRNA Vaccine Candidate for Triple-Negative Breast Cancer: Computational Design and Immune Response Prediction
Background: Why target LRP6 with a vaccine?
A computational study designed a messenger RNA (mRNA) vaccine candidate targeting the LRP6 protein in triple-negative breast cancer (TNBC). The researchers analyzed target expression in public patient data and combined antigen regions predicted to be recognized by the immune system to predict the candidate’s structure and immune responses. They did not conduct cell or animal experiments to test the candidate’s anticancer effects, or clinical trials.
TNBC lacks estrogen and progesterone receptors and human epidermal growth factor receptor 2 (HER2). With recurrence and treatment resistance posing challenges, the researchers focused on LRP6, a co-receptor in Wnt signaling, which is involved in cell proliferation and other processes. In breast cancer data from The Cancer Genome Atlas (TCGA), LRP6 expression was higher in triple-negative tumors than in other breast cancers (p=0.041). This observation supports the choice of target; it is distinct from evidence of the vaccine’s therapeutic efficacy.
Key findings: Computational assessment of epitope combinations and immune responses
The researchers selected five LRP6 epitopes predicted to be recognized by each of three cell types: cytotoxic T cells, helper T cells, and B cells. They screened candidates using predicted antigenicity, toxicity, allergenicity, and other properties, then combined them with linker sequences and components intended to support immune responses. The protein construct analyzed for physicochemical properties was 431 amino acids long, with a molecular weight of approximately 47.6 kDa. Its instability index was calculated as 38.3, within the computationally classified stable range; this is not a measurement of the storage stability of an actual mRNA formulation.
Population coverage calculated from the selected epitopes and the population distribution of human leukocyte antigen (HLA) types was 99.04%. This metric estimates how widely HLA types capable of presenting the selected epitopes are distributed in a population. It does not mean vaccine efficacy or suitability for vaccination has been demonstrated in that proportion of people.
Molecular docking assessed interactions between the candidate protein and HLA and Toll-like receptors (TLRs). ClusPro scores included −812.0 for HLA-A*02:01 and −1339.5 for TLR9. These computational scores alone cannot establish actual binding affinity or receptor activation.
The immune simulation assumed three doses given 28 days apart. At day 365, model outputs showed more than 200 memory B cells and more than 3,000 helper T cells. IgG1 antibody and interferon gamma (IFN-γ) responses were also predicted, but these are not cell counts or measures of immune persistence observed in people. After codon optimization, the codon adaptation index (CAI) was 0.94 and GC content was 58.37%. These computational results indicate high compatibility with codon usage in human cells; actual expression levels were not measured.
Significance and outlook: Anticancer efficacy and safety in normal tissues remain to be tested
The study presents a candidate LRP6-targeting vaccine and a design rationale for evaluation in follow-up experiments. However, LRP6 is also expressed in normal tissues, so the risk of autoimmunity must be assessed. The predicted solubility of the protein construct was also low, at 0.291. This value cannot readily be interpreted as the solubility or delivery performance of an mRNA formulation.
The immune simulation did not explicitly account for immune exhaustion, induction of regulatory T cells, changes in the immune checkpoint protein PD-1, or the risk of cytokine storm. The researchers plan to test antigen presentation and antigen-specific immune responses at the cellular level, assess tumor progression and survival in mouse models, and optimize lipid nanoparticle delivery systems. Clinical efficacy, personalized treatment, and prolonged survival remain unproven. Detailed design and analyses are presented in the full Cancer Reports paper.
BACKGROUND: Triple-negative breast cancer (TNBC) presents a poorer prognosis than other breast cancer subtypes, attributed to its aggressive nature and the lack of specific therapeutic interventions. TNBC has high recurrence rates and limited survival despite current therapies, emphasizing the critical need for improved treatment options. TNBC exhibits increased levels of LRP6 expression, which is linked to tumor-related features such as growth, metastasis, poor prognosis, resistance to chemotherapy, and invasion. Therefore, LRP6 offers a promising option for therapeutic intervention in breast cancer. AIMS: This research aims to use in silico and bioinformatics techniques to develop an mRNA vaccine that specifically targets the LRP6 antigen. METHODS AND RESULTS: The final vaccine construct comprised 431 amino acids, with a molecular weight of 47.5 kDa, theoretical pI of 5.11, and an instability index of 38.3 indicating stability. Population coverage analysis showed broad global coverage of 99.04%. Molecular docking revealed strong binding affinities to immune receptors, including HLA-A0201 (-812.0), HLA-A0301 (-707.1), HLA-DRB1*0101 (-955.7), and TLR9 (-1339.5). Immune simulation predicted high titers of IgG1 antibodies, sustained memory B cell populations (> 200 by Day 365), elevated CD4+ T cells (> 3000), and robust IFN-γ responses. Codon optimization yielded a high CAI value of 0.94 and GC content of 58.37%, supporting efficient expression in human systems. CONCLUSION: Collectively, these results suggest that the designed LRP6-targeted mRNA vaccine could induce durable humoral and cellular immunity against TNBC and warrants further experimental validation.
This design could help prioritize follow-up experiments. Researchers would first test whether the proposed epitope combination actually induces antigen presentation and whether an LRP6-specific T-cell response occurs. The researchers’ proposed validation plan includes assessing dendritic-cell uptake and antigen presentation, as well as measuring IFN-γ secretion with an ELISPOT assay. Subsequent studies would need to evaluate tumor progression and survival in animal models and examine possible damage to normal tissues. Delivery-system development also requires measurements of actual expression, delivery, and safety, rather than judging formulation performance solely from computationally predicted protein properties. These results provide a starting point for such validation; they do not yet establish a treatment option or survival benefit for patients.